#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

Start What Strand does The Boston dinner The image of a body riddled with cancer What stuck for the muggles in the pitch deck A good drug vs. a good product Tricking cancer into snitching on itself The abscopal effect Potency, specificity, and delivery First principles thinking The precipice of a revolution The thousand people in the room Psychedelic medicine as a cautionary tale What actually catches a policymaker’s attention Breakthrough vs. incremental What’s in it for the policymakers? The 80/20 wish list Australia’s CTN system Sheep, psychedelics, and red-tape arbitrage China’s clinical-trial flywheel vs. slow-motion American loss The bicoastal biotech ethos Can the FDA actually pull this off? The Sophie’s Choice of pharma development Lost arts of founder mode Rockets for tumors, T-cells, and beyond Viral in policy circles The Washington Post headline and the PickFu split test Solution-first storytelling RNA medicine and platform therapeutics Moderna’s 62 days Uber Eats and the de-risked launch CEO blockers Where’s biotech’s SpaceX moment? Elon Musk betting black on the wheel AWS and the post-conviction / pre-consensus window COVID politicization Insulin, growth hormone, and the original platform story Biotech as pharma’s little brother More recent role models, Apple edition Art Levinson, Steve Jobs, and the biotech-tech crossover The iPhone as a delivery platform Spotify’s problem and the future of bespoke medicine Baby KJ and the limits of liver-only solutions Parting thoughts. Start. What Strand does. The Boston dinner. The image of a body riddled with cancer. What stuck for the muggles in the pitch deck. A good drug vs. a good product. Tricking cancer into snitching on itself. The abscopal effect. Potency, specificity, and delivery. First principles thinking. The precipice of a revolution. The thousand people in the room. Psychedelic medicine as a cautionary tale. What actually catches a policymaker’s attention. Breakthrough vs. incremental. The 80/20 wish list. Australia’s CTN system. Sheep, psychedelics, and red-tape arbitrage. China’s clinical-trial flywheel vs. slow-motion American loss. The bicoastal biotech ethos. The Sophie’s Choice of pharma development. Lost arts of founder mode. Rockets for tumors, T-cells, and beyond. Viral in policy circles. The Washington Post headline and the PickFu split test. Solution-first storytelling. RNA medicine and platform therapeutics. Moderna’s 62 days. Uber Eats and the de-risked launch. CEO blockers. Elon Musk betting black on the wheel. AWS and the post-conviction / pre-consensus window. COVID politicization. Insulin, growth hormone, and the original platform story. Biotech as pharma’s little brother. More recent role models, Apple edition. Art Levinson, Steve Jobs, and the biotech-tech crossover. The iPhone as a delivery platform. Spotify’s problem and the future of bespoke medicine. Baby KJ and the limits of liver-only solutions.